Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study

Background Migraine preventive medications are used to reduce headache frequency, severity, and duration. In patients with chronic migraine (CM), reversion to episodic migraine (EM) is an important treatment goal. Objective To evaluate the effect of fremanezumab on the rate of reversion from CM to E...

Full description

Saved in:
Bibliographic Details
Published in:Headache 2020-11, Vol.60 (10), p.2444-2453
Main Authors: Lipton, Richard B., Cohen, Joshua M., Bibeau, Kristen, Galic, Maja, Seminerio, Michael J., Ramirez Campos, Verena, Halker Singh, Rashmi B., Ailani, Jessica
Format: Article
Language:English
Subjects:
all headache
all pain
Botulinum toxin type A
clinical trials randomized controlled
Headache
Headaches
Migraine
Monoclonal antibodies
Reduction
Research Submission
Research Submissions
Topiramate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Migraine preventive medications are used to reduce headache frequency, severity, and duration. In patients with chronic migraine (CM), reversion to episodic migraine (EM) is an important treatment goal. Objective To evaluate the effect of fremanezumab on the rate of reversion from CM to EM. Methods This phase 3, randomized, double‐blind, placebo‐controlled, parallel‐group trial included a 28‐day pretreatment period and a 3‐month treatment period. Patients with CM received subcutaneous fremanezumab quarterly (675 mg at baseline) or monthly (675 mg at baseline; 225 mg at Weeks 4 and 8), or placebo. Post hoc analyses evaluated the proportion of patients who reverted from CM to EM, defined as either a reduction to an average of
ISSN:0017-8748
1526-4610
DOI:10.1111/head.13997